文献速递慢性肾脏病肾血管病与高血压

糖尿病心肾保护:超越糖尿病分型

Kidney and Cardiovascular Protection in Diabetes: Beyond Diabetes Typology.
PubMed 文献 · Am J Kidney Dis · 2026-03-04

该观点文章探讨了非2型糖尿病人群在心肾保护治疗中的证据缺口,指出其常被临床试验排除,并呼吁通过替代终点小型试验和真实世界研究来扩展新疗法的适用人群。

要点

  • 非2型糖尿病患者常被排除在心肾保护临床试验之外
  • 新疗法在缺乏证据人群中的推广往往不理想
  • 需开展替代终点试验和真实世界研究以补充证据

核心结论

  • 非2型糖尿病人群的心肾保护治疗证据不足,需专门研究以支持新疗法的扩展应用。

研究设计与样本

  • 观点性文章,批判性审视非2型糖尿病的特点及新疗法的现有证据。

主要发现

  • 非2型糖尿病患者常因假设的事件风险、发病机制和不良事件潜力不同而被排除在临床试验之外。
  • 即使有明确证据,新疗法的实际采用率也往往令人失望地低。

临床怎么用

  • 临床应关注非2型糖尿病人群的心肾保护治疗证据缺口,并审慎评估新疗法的适用性。

局限性

  • 文章为观点性论述,未提供原始研究数据或系统评价。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite the abundance of new therapies designed to delay or prevent kidney and cardiovascular events in people with type 2 diabetes mellitus (T2DM), a stark gap remains in the evidence supporting their efficacy and safety for other types of diabetes. Individuals without T2DM are frequently excluded from clinical trials based on the assumptions that their event risk, pathogenesis, and potential for adverse events differ significantly. It is anticipated that treatments will eventually be expanded to include this population, yet the uptake of new therapies even with clear evidence is often disappointingly low. In this perspective, we critically examine the characteristics of diabetes types other than T2DM and evaluate the available evidence for novel therapies in these underrepresented populations. Future small trials of surrogate end points and real-world studies, including individuals without T2DM, will be essential to understand and use recent advancements in treatments for preventing kidney failure and cardiovascular events and death.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Mottl AK, Sawinski DL, Bjornstad P, et al. Kidney and Cardiovascular Protection in Diabetes: Beyond Diabetes Typology. Am J Kidney Dis. 2026. PMID: 41791642. doi:10.1053/j.ajkd.2025.10.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。